Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Mirabegron confirmed safe and effective for overactive bladder syndrome

12 Jan 2020

Mirabegron may be used to effectively treat overactive bladder (OAB) syndrome without presenting new and pressing safety concerns, a recent study has found.

Pooling from 10 phase 2–4 double-blind, 12-week mirabegron trials, researchers reassessed the efficacy and safety of the drug against OAB syndrome. Safety was evaluated through the occurrence of treatment-emergent adverse events (TEAEs), while bladder diary data were used for the assessment of treatment efficacy.

Both the 25-mg and 50-mg doses of mirabegron significantly improved OAB symptoms relative to placebo. For instance, the mean number of 24-hour incontinence episodes dropped from 2.95±0.10 and 2.51±0.05 at baseline to 1.35±0.08 and 1.10±0.05 at end-of-treatment for either dose, respectively. The change observed with placebo, in comparison, was statistically smaller.

A similar effect was reported for the number of micturitions per 24 hours. Mirabegron 25 and 50 mg induced a decrease of 2.05±0.08 and 2.12±0.04 episodes from baseline to end-of-treatment, respectively, both significantly greater than the placebo treatment’s net change of –1.55±0.05. The same was true for urgency and nocturia episodes per 24 hours.

The mean voided volume was significantly increased after treatment with 25-mg (change, 15.94±1.37) and 50-mg (change, 23.17±0.84) mirabegron, likewise statistically outperforming placebo.

These improvements did not come with new safety signals. TEAEs included dry mouth, constipation, urinary tract infection, tachycardia and treatment-emergent hypertension. However, these occurred more commonly in patients treated with antimuscarinics vs mirabegron. Placebo treatments showed the lowest incidence of TEAEs.

Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.